

PRESS RELEASE

EOS Imaging launches a capital increase through a private placement

Paris, April 20, 2017 – 5.45pm CEST – EOS imaging (Euronext, FR0011191766 – EOSI) (the “Company”), pioneer in 2D/3D orthopaedic medical imaging, today announced the launch of a capital increase by issuance of new shares without pre-emptive rights in favour of qualified investors, in accordance with the 11th and 12th resolutions of the shareholder’s extraordinary general meeting held on June 17th 2015. The transaction involves a maximum of 1,868,000 new shares to be issued, i.e. c. 9.2% of the share capital. Application will be made for the new shares to be admitted on trading on Euronext Paris.

Funds will be raised from domestic and international qualified investors notably excluding the United States, Canada, Australia and Japan, pursuant to Articles L.225-136 of the French Commercial Code (*Code de commerce*) and L. 411-2 II of the French Monetary and Financial Code (*Code monétaire et financier*) (the “**Private Placement**”). The net proceeds of the private placement will be used by EOS Imaging to strengthen its capital, in particular to finance investments in product design and industrial processes, aimed at improving the company's operating profitability.

Bpifrance Participations, shareholder holding 9.02% of the Company’s capital, has undertaken to subscribe to the capital increase, under certain conditions, for a minimum amount of €2.5m and within the limit of 33% of the total raised amount. The Company has not received any other subscription undertaking from others existing shareholders.

The Private Placement will be conducted by way of an accelerated bookbuild offering, at the end of which the number and issue price of the new shares will be set. The accelerated bookbuild offering will commence with immediate effect and is expected to end before markets open tomorrow, subject to acceleration or extension. The Company will announce the results of the Offering as soon as possible after closing of the bookbuilding in a subsequent press release. In accordance with the 12th resolution of the shareholder’s extraordinary general meeting held on June 17th 2015, the issue price of the new shares will be at least equal to the volume weighted average share price of the Company on the regulated market of Euronext Paris over the last ten trading sessions prior to the setting of the issue price, which may be reduced by a discount of at most 20%.

Settlement of the new shares issued in the context of the Private Placement and the new shares’ admission to trading on Euronext Paris is expected to occur on 25th April 2017. The new shares will be admitted to trading on the Euronext regulated market in Paris under ISIN FR0011191766 – EOSI.

In the context of the Private Placement, the Company has entered into a 90-day restriction agreement from the settlement-delivery date and Bpifrance Participations has signed a lock-up agreement with regard to all the Company’s shares held during the 90 days that follow the Private Placement’s settlement-delivery date. These agreements may be waived by the Lead Manager and Bookrunner.

For more information, please visit www.eos-imaging.com.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

www.eos-imaging.com

PRESS RELEASE

EOS imaging is an “*Entreprise Innovante*” (innovative business) for the FCPI Bpifrance Financement.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI



About EOS imaging

EOS imaging Group designs, develops, and markets EOS[®], an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Group is authorized to market in 51 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2016 revenues of €30.8 million and employs 129 people at December 2016, including an R&D team of 43 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

Contacts:

Anne Renevot

CFO

Ph: +33 (0)1 55 25 61 24

investors@eos-imaging.com

NewCap

Financial communication and investor relations

Pierre Laurent / Valentine Brouchet

Ph: +33 (0)1 44 71 94 96

eosimaging@newcap.eu



PRESS RELEASE

Disclaimer

This announcement does not, and shall not, in any circumstances constitute a public offering nor an invitation to solicit the interest of the public in France, the United States, or in any other jurisdiction, in connection with any offer.

The distribution of this document may, in certain jurisdictions, be restricted by local legislations. Persons into whose possession this document comes are required to inform themselves about and to observe any such potential local restrictions.

*This announcement is not an advertisement and not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003, as amended (the “**Prospectus Directive**”).*

With respect to the member States of the European Economic Area, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member State. As a result, the securities may not and will not be offered in any relevant member State except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive or under any other circumstances which do not require the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member State.

This document does not constitute an offer to the public in France and the securities referred to in this document can only be offered or sold in France pursuant to article L. 411-2-II of the French Monetary and Financial Code to (i) providers of third party portfolio management investment services, (ii) qualified investors (investisseurs qualifiés) acting for their own account and/or (iii) a limited group of investors (cercle restreint d’investisseurs) acting for their own account, all as defined in and in accordance with articles L. 411-1, L. 411-2 and D. 411-1 to D. 411-4 and D. 754-1 and D. 764-1 of the French Monetary and Financial Code.

*This document is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order”), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Article 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “**Relevant Persons**”). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.*

This document may not be distributed, directly or indirectly, in or into the United States. This document does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in the United States or any other jurisdiction where such offer may be restricted. The securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or an applicable exemption from registration requirements under the Securities Act. The shares of the Company have not been and will not be registered under the Securities Act, and the Company does not intend to make a public offering of the securities in the United States.

The Lead Manager and Bookrunner in connection with the Private Placement is acting solely for the Company in relation to the placing, and will not be responsible to any other person for providing the protections afforded to its clients nor for providing advice in connection with the matters contained in this announcement. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by the Lead Manager and Bookrunner or by any of its affiliates or agents, as to or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.

www.eos-imaging.com